SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: Pluvia who wrote (291)7/26/2005 1:13:53 AM
From: tnsaf  Read Replies (1) | Respond to of 377
 
As to the issue of not knowing what is the drug, there is a similar situation with Lovenox, which is a complex polysacharide that Aventis has not been able to fully characterize, and it is a $2B drug.

Jason



To: Pluvia who wrote (291)7/31/2005 10:24:35 AM
From: manny_velasco  Read Replies (2) | Respond to of 377
 
Vasogen is an interesting company..playing with the mother of all short squeeze again?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News